The -carboxyglutamic acid-rich domain of blood coagulation Factor IX is required for the binding of the protein to phospholipid membranes. To investigate the three-dimensional structure of this domain, a synthetic peptide corresponding to residues 1-47 of Factor IX was studied by H NMR spectroscopy. In the absence of metal ions, the proton chemical shift dispersion in the one-dimensional NMR spectrum indicated that the peptide contains regular structural elements. Upon the addition of Ca(II) or Mg(II), large chemical shift changes were observed in the amide proton and methyl proton regions of the spectrum, consistent with the conformational transitions that metal ions are known to induce in native Factor IX. The apopeptide was studied by two-dimensional NMR spectroscopy at 500 MHz to determine its solution structure. Protons were assigned using total correlation spectroscopy, nuclear Overhauser effect spectroscopy, and double quantum-filtered correlation spectroscopy experiments. Intensities of cross-peaks in the nuclear Overhauser effect spectrum were used to generate a set of interproton distance restraints. The structure of the apopeptide was then calculated using distance geometry methods. There are three structural elements in the apopeptide that are linked by a flexible polypeptide backbone. These elements include a short amino-terminal tetrapeptide loop (amino acids 6-9), the disulfide-containing hexapeptide loop (amino acids 18-23), and a carboxyl-terminal helix (amino acids 37-46). Amide hydrogen exchange kinetics indicate that the majority of the peptide is solvent accessible, except in the carboxyl-terminal element. The structured regions in the apopeptide are insufficient to support phospholipid binding, indicating the importance of additional structural features in the Ca(II)-stabilized conformer.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				N. P. Gudderra, J. M. C. Ribeiro, and J. F. Andersen Structural Determinants of Factor IX(a) Binding in Nitrophorin 2, a Lipocalin Inhibitor of the Intrinsic Coagulation Pathway J. Biol. Chem., July 1, 2005; 280(26): 25022 - 25028. [Abstract] [Full Text] [PDF]

				B. A. Lwaleed, R. S. Greenfield, J. Hicks, B. R. Birch, and A. J. Cooper Quantitation of Seminal Factor IX and Factor IXa in Fertile, Nonfertile, and Vasectomy Subjects: A Step Closer Toward Identifying a Functional Clotting System in Human Semen J Androl, January 1, 2005; 26(1): 146 - 152. [Abstract] [Full Text] [PDF]

				M. Huang, B. C. Furie, and B. Furie Crystal Structure of the Calcium-stabilized Human Factor IX Gla Domain Bound to a Conformation-specific Anti-factor IX Antibody J. Biol. Chem., April 2, 2004; 279(14): 14338 - 14346. [Abstract] [Full Text] [PDF]

				M. D. Blostein, B. C. Furie, I. Rajotte, and B. Furie The Gla Domain of Factor IXa Binds to Factor VIIIa in the Tenase Complex J. Biol. Chem., August 15, 2003; 278(33): 31297 - 31302. [Abstract] [Full Text] [PDF]

				O. D. Christophe, P. J. Lenting, G. Cherel, M. Boon-Spijker, J.-M. Lavergne, R. Boertjes, M.-E. Briquel, A. de Goede-Bolder, J. Goudemand, S. Gaillard, et al. Functional mapping of anti-factor IX inhibitors developed in patients with severe hemophilia B Blood, September 1, 2001; 98(5): 1416 - 1423. [Abstract] [Full Text] [PDF]

				B. Lind, A. H. Johnsen, and S. Thorsen Naturally Occurring Arg-1 to His Mutation in Human Protein C Leads to Aberrant Propeptide Processing and Secretion of Dysfunctional Protein C Blood, April 15, 1997; 89(8): 2807 - 2816. [Abstract] [Full Text] [PDF]

				S. J. Freedman, M. D. Blostein, J. D. Baleja, M. Jacobs, B. C. Furie, and B. Furie Identification of the Phospholipid Binding Site in the Vitamin K-dependent Blood Coagulation Protein Factor IX J. Biol. Chem., July 5, 1996; 271(27): 16227 - 16236. [Abstract] [Full Text] [PDF]